Georgios Ar Alevizopoulos

Dr. Georgios Ar Alevizopoulos


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in The European Journal of Psychiatry
Verified
Journal Article
Closed access
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
MNMaria Nystazaki
Maria Nystazaki

14 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
GDGeorgios I. Detorakis
Georgios I. Detorakis
AVAntonios Vakis
Antonios Vakis
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis

Background: Managing comorbid psychotic disorders and cognitive impairments in community settings is clinically challenging. This study evaluates the real-world impact of Long-Acting Injectable (LAI) antipsychotics on psychiatric hospitalizations, clinical severity, and Quality of Life (QoL) in community-dwelling patients with intellectual or cognitive deficits. Methods: A symmetric, matched-pairs pre-post design was utilized to analyze a targeted cohort of 41 patients from the “DNAng” research project over a six-month observation window. The sample was stratified into two subgroups: a non-hospitalized cohort with primary intellectual disabilities (n = 22) and a previously hospitalized cohort characterized by neuroprogressive cognitive decline and dual diagnoses (n = 19). Main outcomes were tracked using the Clinical Global Impression-Severity (CGI-S) scale and the WHOQOL-BREF Global QoL item. Results: Baseline χ² testing revealed significant sociodemographic and diagnostic differences between the subcohorts (p < 0.05). Following LAI initiation, both groups demonstrated profound, statistically significant clinical improvements. In the non-hospitalized group, CGI-S decreased from 5.77 ± 0.86 to 3.09 ± 0.92 (p < 0.001; δ = 0.97) and QoL rose from 0.59 ± 0.50 to 3.13 ± 0.83 (p < 0.001; δ = -1.00). In the hospitalized group, total admissions plummeted from 2.10 ± 1.28 to 0.05 ± 0.22 (p = 0.0002; δ = 0.98), while involuntary prosecutor-ordered admissions collapsed to near-zero. CGI-S decreased to 3.78 ± 1.08 (p = 0.0003) and QoL reached 3.05 ± 0.84 (p = 0.0001). Conclusions: LAI antipsychotics provide a vital clinical safety net for cognitively vulnerable psychiatric populations, significantly reducing clinical severity, optimizing subjective well-being, and virtually eliminating traumatic and costly involuntary hospitalizations.


30 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
MAMaria Alevizopoulou
Maria Alevizopoulou
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
Introduction: The aim is to investigate the possibility of altering the delusional perceptions of psychotic patients by exposing them to a cognitively flexible virtual environment. A flexible vir-tual reality (VR) environment could challenge and enhance the ability to adapt to changing situa-tions and generate novel solutions to core psychotic symptoms. Materials and methods: A systematic review was conducted using different combinations of keywords in different databases. This study was conducted using the PRISMA statement. Results: There is a growing literature on the use of VR to manipulate and normalise perceptual distortions in psychosis. Over the last decade, the number of published studies on VR in mental health has increased 14-fold. Conclusions: A cognitive flexibility virtual environment can alter delusional perception by ex-posing the person to different scenarios that require them to question their assumptions, test their hypotheses, and revise their beliefs. Commonly used biosensors measure heart rate, skin con-ductance and body temperature in relation to different emotional states. Recently, there has been a major shift towards the use of neuroimaging techniques to better understand the pathophysiology of mental disorders. This is where the new wave of biosensor-integrated virtual reality (VR) sys-tems comes in.

3 May 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
GAGeorgios Anastasiou
Georgios Anastasiou
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
MAMaria Alevizopoulou
Maria Alevizopoulou
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
Psychosis presents significant treatment challenges, and standard Cognitive Behavioral Therapy for psychosis often faces limitations due to patient engagement issues and reliance on subjective self-reporting. The integration of Virtual Reality (VR), physiological biosensors, and artificial intelligence offers a transformative opportunity to address these challenges. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. A thorough literature search was performed across seven databases. Twelve randomized controlled trials involving 1504 participants were included to assess VR-assisted CBT, VR treatment, and AVATAR therapy. Meta-analyses showed that VR interventions significantly decreased auditory verbal hallucinations (pooled SMD = −0.24, p = 0.0011) and paranoid thoughts (SMD = −0.26, p < 0.0001) compared to control conditions. This review supports integrating multi-modal biosensors to collect real-time, objective physiological data. Such integration enables the development of AI-driven, closed-loop systems that dynamically adjust the virtual environment based on the patient’s physiological state. VR-assisted therapies effectively reduce positive symptoms of psychosis. Incorporating biosensors is a crucial step toward a data-driven approach for personalized, closed-loop psychiatric care. Future efforts should focus on large-scale clinical trials, biomarker validation, and robust ethical frameworks to ensure safe and effective implementation.

5 November 2026 in Psychiatry International
Verified
Journal Article
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
GDGeorgios I. Detorakis
Georgios I. Detorakis
AVAntonios Vakis
Antonios Vakis
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis
Background: Managing comorbid psychotic disorders and cognitive impairments in community settings is clinically challenging. This study evaluates the real-world outcomes associated with long-acting injectable (LAI) antipsychotics regarding psychiatric hospitalizations, clinical severity, and quality of life (QoL) in community-dwelling patients with intellectual or cognitive deficits. Methods: A retrospective, uncontrolled pre–post cohort study was conducted analyzing observational data from 41 patients enrolled in the “DNAng” research project over a six-month observation window. The sample was stratified into two subgroups: a non-hospitalized cohort with primary intellectual disabilities (n = 22) and a previously hospitalized cohort characterized by cognitive decline and dual diagnoses (n = 19). Main outcomes were tracked using the Clinical Global Impression-Severity (CGI-S) scale and the WHOQOL-BREF Global QoL item. Results: Baseline χ2 testing revealed significant sociodemographic and diagnostic differences between the subcohorts (p < 0.05). Following LAI initiation, both groups demonstrated statistically significant longitudinal changes. In the non-hospitalized group, CGI-S scores decreased from 5.77 ± 0.86 to 3.09 ± 0.92 (unadjusted p < 0.001; paired Cohen’s d = 3.01, 95% CI: [2.03, 3.99]) and QoL scores rose from 0.59 ± 0.50 to 3.13 ± 0.83 (unadjusted p < 0.001; paired Cohen’s d = −3.71, 95% CI: [−4.88, −2.53]). In the previously hospitalized group, total admissions decreased from a baseline median of 2.0 (IQR: 1.0–3.0) to a post-treatment median of 0.0 (IQR: 0.0–0.0) (Wilcoxon unadjusted p = 0.0002; paired Cohen’s d = 2.23, 95% CI: [1.39, 3.07]), accompanied by an observed decline in involuntary prosecutor-ordered admissions. Furthermore, CGI-S scores decreased to 3.78 ± 1.08 (unadjusted p = 0.0003; paired Cohen’s d = 2.22, 95% CI: [1.38, 3.06]), and QoL scores reached 3.05 ± 0.84 (unadjusted p = 0.0001; paired Cohen’s d = −3.64, 95% CI: [−4.88, −2.40]). Conclusions: In this retrospective evaluation, LAI antipsychotic administration was accompanied by observed reductions in clinical severity, concurrent improvements in subjective well-being scores, and lower rates of involuntary hospitalizations within this cognitively vulnerable population. These findings indicate an association between LAI formulations and clinical stability in community psychiatry, though controlled prospective studies remain essential to establish causal links.